<?xml version='1.0' encoding='utf-8'?>
<document id="9665503"><sentence text="Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers."><entity charOffset="47-58" id="DDI-PubMed.9665503.s1.e0" text="delavirdine" /><entity charOffset="63-72" id="DDI-PubMed.9665503.s1.e1" text="indinavir" /><pair ddi="false" e1="DDI-PubMed.9665503.s1.e0" e2="DDI-PubMed.9665503.s1.e0" /><pair ddi="false" e1="DDI-PubMed.9665503.s1.e0" e2="DDI-PubMed.9665503.s1.e1" /></sentence><sentence text="The potential pharmacokinetic drug-drug interaction between delavirdine, a nonnucleoside analogue reverse transcriptase inhibitor, and indinavir, an inhibitor of HIV protease, was evaluated in healthy volunteers"><entity charOffset="60-71" id="DDI-PubMed.9665503.s2.e0" text="delavirdine" /><entity charOffset="75-88" id="DDI-PubMed.9665503.s2.e1" text="nonnucleoside" /><entity charOffset="135-144" id="DDI-PubMed.9665503.s2.e2" text="indinavir" /><pair ddi="false" e1="DDI-PubMed.9665503.s2.e0" e2="DDI-PubMed.9665503.s2.e0" /><pair ddi="false" e1="DDI-PubMed.9665503.s2.e0" e2="DDI-PubMed.9665503.s2.e1" /><pair ddi="false" e1="DDI-PubMed.9665503.s2.e0" e2="DDI-PubMed.9665503.s2.e2" /><pair ddi="false" e1="DDI-PubMed.9665503.s2.e1" e2="DDI-PubMed.9665503.s2.e1" /><pair ddi="false" e1="DDI-PubMed.9665503.s2.e1" e2="DDI-PubMed.9665503.s2.e2" /></sentence><sentence text=" Subjects received a single 800-mg dose of indinavir sulfate on day 1 (baseline)"><entity charOffset="43-60" id="DDI-PubMed.9665503.s3.e0" text="indinavir sulfate" /></sentence><sentence text=" Delavirdine mesylate 400 mg was administered three times daily on days 2 through 10"><entity charOffset="1-21" id="DDI-PubMed.9665503.s4.e0" text="Delavirdine mesylate" /></sentence><sentence text=" On day 9, a single 400-mg dose and on day 10 a single 600-mg dose of indinavir were given along with morning doses of delavirdine"><entity charOffset="70-79" id="DDI-PubMed.9665503.s5.e0" text="indinavir" /><entity charOffset="119-130" id="DDI-PubMed.9665503.s5.e1" text="delavirdine" /><pair ddi="false" e1="DDI-PubMed.9665503.s5.e0" e2="DDI-PubMed.9665503.s5.e0" /><pair ddi="false" e1="DDI-PubMed.9665503.s5.e0" e2="DDI-PubMed.9665503.s5.e1" /></sentence><sentence text=" Pharmacokinetic evaluations of indinavir were made on days 1, 9, and 10, and of delavirdine on days 8, 9, and 10"><entity charOffset="32-41" id="DDI-PubMed.9665503.s6.e0" text="indinavir" /><entity charOffset="81-92" id="DDI-PubMed.9665503.s6.e1" text="delavirdine" /><pair ddi="false" e1="DDI-PubMed.9665503.s6.e0" e2="DDI-PubMed.9665503.s6.e0" /><pair ddi="false" e1="DDI-PubMed.9665503.s6.e0" e2="DDI-PubMed.9665503.s6.e1" /></sentence><sentence text=" Fourteen healthy male volunteers completed the study" /><sentence text=" Single doses of indinavir had no clinically important effects on the pharmacokinetics of delavirdine"><entity charOffset="17-26" id="DDI-PubMed.9665503.s8.e0" text="indinavir" /><entity charOffset="90-101" id="DDI-PubMed.9665503.s8.e1" text="delavirdine" /><pair ddi="false" e1="DDI-PubMed.9665503.s8.e0" e2="DDI-PubMed.9665503.s8.e0" /><pair ddi="false" e1="DDI-PubMed.9665503.s8.e0" e2="DDI-PubMed.9665503.s8.e1" /></sentence><sentence text=" Mean indinavir Cmax values for the 400-mg and 600-mg doses administered concomitantly with delavirdine were dose proportionally lower than that observed following the 800-mg dose administered alone"><entity charOffset="6-15" id="DDI-PubMed.9665503.s9.e0" text="indinavir" /><entity charOffset="92-103" id="DDI-PubMed.9665503.s9.e1" text="delavirdine" /><pair ddi="false" e1="DDI-PubMed.9665503.s9.e0" e2="DDI-PubMed.9665503.s9.e0" /><pair ddi="false" e1="DDI-PubMed.9665503.s9.e0" e2="DDI-PubMed.9665503.s9.e1" /></sentence><sentence text=" Mean Tmax values were similar and ranged from 1" /><sentence text="0 +/- 0" /><sentence text="3/hour for indinavir 800 mg administered alone to 1" /><sentence text="3 +/- 0" /><sentence text="4/hour for indinavir 600 mg administered with delavirdine"><entity charOffset="46-57" id="DDI-PubMed.9665503.s14.e0" text="delavirdine" /></sentence><sentence text=" These results indicate that delavirdine had no clinically important effect on the rate of indinavir absorption"><entity charOffset="29-40" id="DDI-PubMed.9665503.s15.e0" text="delavirdine" /><entity charOffset="91-100" id="DDI-PubMed.9665503.s15.e1" text="indinavir" /><pair ddi="false" e1="DDI-PubMed.9665503.s15.e0" e2="DDI-PubMed.9665503.s15.e0" /><pair ddi="false" e1="DDI-PubMed.9665503.s15.e0" e2="DDI-PubMed.9665503.s15.e1" /></sentence><sentence text=" In contrast, the mean indinavir AUC0-infinity, value following the 400-mg dose administered with delavirdine was only 14% lower than the baseline value determined for the 800-mg indinavir dose (25,400 +/- 6960 nM hour versus 29,600 +/- 7920 nM hour), and the mean indinavir AUC0-infinity value for the 600-mg indinavir dose administered with delavirdine (42,700 +/- 9800 nM hour) was 44% greater than the baseline value"><entity charOffset="98-109" id="DDI-PubMed.9665503.s16.e0" text="delavirdine" /><entity charOffset="343-354" id="DDI-PubMed.9665503.s16.e1" text="delavirdine" /><pair ddi="false" e1="DDI-PubMed.9665503.s16.e0" e2="DDI-PubMed.9665503.s16.e0" /><pair ddi="false" e1="DDI-PubMed.9665503.s16.e0" e2="DDI-PubMed.9665503.s16.e1" /></sentence><sentence text=" All differences among mean AUC0-infinity values were statistically significant" /><sentence text=" Mean indinavir half-life values were slightly longer when indinavir was given in a dose with delavirdine than when indinavir was administered alone"><entity charOffset="6-15" id="DDI-PubMed.9665503.s18.e0" text="indinavir" /><entity charOffset="59-68" id="DDI-PubMed.9665503.s18.e1" text="indinavir" /><entity charOffset="94-105" id="DDI-PubMed.9665503.s18.e2" text="delavirdine" /><entity charOffset="116-125" id="DDI-PubMed.9665503.s18.e3" text="indinavir" /><pair ddi="false" e1="DDI-PubMed.9665503.s18.e0" e2="DDI-PubMed.9665503.s18.e0" /><pair ddi="false" e1="DDI-PubMed.9665503.s18.e0" e2="DDI-PubMed.9665503.s18.e1" /><pair ddi="false" e1="DDI-PubMed.9665503.s18.e0" e2="DDI-PubMed.9665503.s18.e2" /><pair ddi="false" e1="DDI-PubMed.9665503.s18.e0" e2="DDI-PubMed.9665503.s18.e3" /><pair ddi="false" e1="DDI-PubMed.9665503.s18.e1" e2="DDI-PubMed.9665503.s18.e1" /><pair ddi="false" e1="DDI-PubMed.9665503.s18.e1" e2="DDI-PubMed.9665503.s18.e2" /><pair ddi="false" e1="DDI-PubMed.9665503.s18.e1" e2="DDI-PubMed.9665503.s18.e3" /><pair ddi="false" e1="DDI-PubMed.9665503.s18.e2" e2="DDI-PubMed.9665503.s18.e2" /><pair ddi="false" e1="DDI-PubMed.9665503.s18.e2" e2="DDI-PubMed.9665503.s18.e3" /></sentence><sentence text=" These results suggest that delavirdine inhibits metabolism of indinavir and support the possibility of a reduction in the magnitude or frequency of indinavir dosage when given in combination with delavirdine"><entity charOffset="28-39" id="DDI-PubMed.9665503.s19.e0" text="delavirdine" /><entity charOffset="63-72" id="DDI-PubMed.9665503.s19.e1" text="indinavir" /><entity charOffset="149-158" id="DDI-PubMed.9665503.s19.e2" text="indinavir" /><entity charOffset="197-208" id="DDI-PubMed.9665503.s19.e3" text="delavirdine" /><pair ddi="false" e1="DDI-PubMed.9665503.s19.e0" e2="DDI-PubMed.9665503.s19.e0" /><pair ddi="false" e1="DDI-PubMed.9665503.s19.e0" e2="DDI-PubMed.9665503.s19.e1" /><pair ddi="false" e1="DDI-PubMed.9665503.s19.e0" e2="DDI-PubMed.9665503.s19.e2" /><pair ddi="false" e1="DDI-PubMed.9665503.s19.e0" e2="DDI-PubMed.9665503.s19.e3" /><pair ddi="false" e1="DDI-PubMed.9665503.s19.e1" e2="DDI-PubMed.9665503.s19.e1" /><pair ddi="false" e1="DDI-PubMed.9665503.s19.e1" e2="DDI-PubMed.9665503.s19.e2" /><pair ddi="false" e1="DDI-PubMed.9665503.s19.e1" e2="DDI-PubMed.9665503.s19.e3" /><pair ddi="false" e1="DDI-PubMed.9665503.s19.e2" e2="DDI-PubMed.9665503.s19.e2" /><pair ddi="false" e1="DDI-PubMed.9665503.s19.e2" e2="DDI-PubMed.9665503.s19.e3" /></sentence><sentence text="" /></document>